Q&A: Meet Gabriel Levin, MD, CureLab Oncology’s Director of Oncology
September 26, 2025
A novel DNA-based therapy achieves significant increase in overall survival in platinum resistant ovarian cancer
January 12, 2026Novel DNA Therapy Elenagen Shows Promise for Platinum-Resistant Ovarian Cancer
Clinical study in International Journal of Gynecological Cancer shows promising results for platinum-resistant ovarian cancer. Elenagen DNA therapy with gemcitabine benefits women with PROC and high CA-125 levels.
Novel DNA Therapy Elenagen Shows Promise for Platinum-Resistant Ovarian Cancer
A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women facing platinum-resistant ovarian cancer (PROC). Researchers evaluated a novel DNA-based therapy, Elenagen, administered in combination with the standard chemotherapy gemcitabine in women with PROC and elevated CA-125.
The study focused on assessing the efficacy and safety of Elenagen in treating platinum-resistant ovarian cancer, a challenging condition with limited treatment options. Platinum resistance in ovarian cancer often leads to poor prognosis and limited response to standard therapies, making the development of novel treatment approaches crucial.
Elenagen, a DNA-based therapy, works by targeting specific genetic pathways involved in cancer progression.
By leveraging the unique properties of DNA, Elenagen aims to enhance the body's natural defense mechanisms against cancer cells, potentially overcoming resistance to traditional chemotherapy agents like platinum-based drugs.
The combination of Elenagen with gemcitabine represents a promising strategy to improve outcomes for women with platinum-resistant ovarian cancer. Gemcitabine, a commonly used chemotherapy drug, works by interfering with the growth and spread of cancer cells, complementing the targeted approach of Elenagen.
The study enrolled a cohort of women with PROC and elevated CA-125 levels, a biomarker often associated with ovarian cancer. Patients received a tailored treatment regimen consisting of Elenagen and gemcitabine, with regular monitoring of treatment response and side effects.
Preliminary results from the study indicate encouraging outcomes, with a notable proportion of patients showing disease stabilization or partial response to the combination therapy. Reductions in CA-125 levels were observed in many participants, suggesting a potential positive impact on tumor burden and disease progression.
Furthermore, the safety profile of the Elenagen-gemcitabine combination was generally favorable, with manageable side effects reported by the majority of patients. Adverse events were consistent with those expected from standard chemotherapy regimens, highlighting the tolerability of the novel DNA therapy in this patient population.
These findings underscore the potential of Elenagen as a valuable addition to the treatment armamentarium for platinum-resistant ovarian cancer. By harnessing the power of DNA-based therapy in combination with established chemotherapy agents, clinicians may offer new hope to women facing this challenging disease.
Future research efforts will focus on expanding the clinical evidence supporting the use of Elenagen in PROC and exploring its efficacy in different patient populations. Continued investigation into the mechanisms of action and long-term outcomes associated with this innovative therapy will be essential for optimizing treatment strategies and improving patient outcomes.
In conclusion, the promising results from the study highlight the potential of Elenagen as a novel and effective treatment option for women with platinum-resistant ovarian cancer. The combination of Elenagen with gemcitabine offers a targeted approach to overcoming drug resistance and improving clinical outcomes in this challenging patient population.
